These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15705743)

  • 1. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine.
    Charlier HA; Olson RD; Thornock CM; Mercer WK; Olson DR; Broyles TS; Muhlestein DJ; Larson CL; Cusack BJ; Shadle SE
    Mol Pharmacol; 2005 May; 67(5):1505-12. PubMed ID: 15705743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol.
    Olson RD; Li X; Palade P; Shadle SE; Mushlin PS; Gambliel HA; Fill M; Boucek RJ; Cusack BJ
    Toxicol Appl Pharmacol; 2000 Dec; 169(2):168-76. PubMed ID: 11097869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of drugs with muscle-related side effects and affinity for calsequestrin on the calcium regulatory function of sarcoplasmic reticulum microsomes.
    Kim E; Tam M; Siems WF; Kang C
    Mol Pharmacol; 2005 Dec; 68(6):1708-15. PubMed ID: 16141311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between cardiac calsequestrin and drugs with known cardiotoxicity.
    Park IY; Kim EJ; Park H; Fields K; Dunker AK; Kang C
    Mol Pharmacol; 2005 Jan; 67(1):97-104. PubMed ID: 15492117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A calcium-induced calcium release mechanism mediated by calsequestrin.
    Lee YS; Keener JP
    J Theor Biol; 2008 Aug; 253(4):668-79. PubMed ID: 18538346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifluoperazine: a rynodine receptor agonist.
    Qin J; Zima AV; Porta M; Blatter LA; Fill M
    Pflugers Arch; 2009 Aug; 458(4):643-51. PubMed ID: 19277699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of calsequestrin over-expression on excitation-contraction coupling in isolated rabbit cardiomyocytes.
    Miller SL; Currie S; Loughrey CM; Kettlewell S; Seidler T; Reynolds DF; Hasenfuss G; Smith GL
    Cardiovasc Res; 2005 Sep; 67(4):667-77. PubMed ID: 15913577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical characterization of calsequestrin-binding 30-kDa protein in sarcoplasmic reticulum of skeletal muscle.
    Kagari T; Yamaguchi N; Kasai M
    Biochem Biophys Res Commun; 1996 Oct; 227(3):700-6. PubMed ID: 8885997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential adverse interaction of human cardiac calsequestrin.
    Kang C; Nissen MS; Sanchez EJ; Lam KS; Milting H
    Eur J Pharmacol; 2010 Nov; 646(1-3):12-21. PubMed ID: 20713040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Rouse W; Riegler F
    Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Egr-1 negatively regulates calsequestrin expression and calcium dynamics in ventricular cells.
    Kasneci A; Kemeny-Suss NM; Komarova SV; Chalifour LE
    Cardiovasc Res; 2009 Mar; 81(4):695-702. PubMed ID: 19103607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Anthracycline Metabolite Doxorubicinol Abolishes RyR2 Sensitivity to Physiological Changes in Luminal Ca
    Hanna AD; Lam A; Thekkedam C; Willemse H; Dulhunty AF; Beard NA
    Mol Pharmacol; 2017 Nov; 92(5):576-587. PubMed ID: 28916620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calsequestrin mediates changes in spontaneous calcium release profiles.
    Tania N; Keener JP
    J Theor Biol; 2010 Aug; 265(3):359-76. PubMed ID: 20648970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol?
    Cusack BJ; Mushlin PS; Voulelis LD; Li X; Boucek RJ; Olson RD
    Toxicol Appl Pharmacol; 1993 Feb; 118(2):177-85. PubMed ID: 8441996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender differences in the modulation of cardiac gene expression by dietary conjugated linoleic acid isomers.
    Tappia PS; Dent MR; Aroutiounova N; Babick AP; Weiler H
    Can J Physiol Pharmacol; 2007; 85(3-4):465-75. PubMed ID: 17612656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors.
    Hanna AD; Janczura M; Cho E; Dulhunty AF; Beard NA
    Mol Pharmacol; 2011 Sep; 80(3):538-49. PubMed ID: 21697274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sp1 transcription factor as a target for anthracyclines: effects on gene transcription.
    Mansilla S; Portugal J
    Biochimie; 2008 Jul; 90(7):976-87. PubMed ID: 18226599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism.
    Shadle SE; Bammel BP; Cusack BJ; Knighton RA; Olson SJ; Mushlin PS; Olson RD
    Biochem Pharmacol; 2000 Nov; 60(10):1435-44. PubMed ID: 11020445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human heart cytosolic reductases and anthracycline cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
    IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute cardiac functional and morphological changes after Anthracycline infusions in children.
    Ganame J; Claus P; Eyskens B; Uyttebroeck A; Renard M; D'hooge J; Gewillig M; Bijnens B; Sutherland GR; Mertens L
    Am J Cardiol; 2007 Apr; 99(7):974-7. PubMed ID: 17398195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.